Metabolon, Inc. has announced that it has entered into a commercialization collaboration for its Quantose™ IR diagnostic with SYNLAB Group. This collaboration is a significant milestone in delivering Metabolon’s technology for precision medicine and diagnostics applications to international markets, which include Europe, Latin America and the Middle East.
Quantose IR a critical pathophysiological state underlying several chronic conditions, which include prediabetes, type 2 diabetes, polycystic ovary syndrome, hypertension and cardiovascular disease. The test will initially be made available in Spain with international expansion planned in 2016. The agreement also provides SYNLAB Group an option to commercialize new Metabolon precision medicine and diagnostics products as they become available.
“Combining SYNLAB Group’s expertise and marketing strength in clinical laboratory services with Metabolon’s technology gives physicians and their patients access to advanced, new laboratory medicine,” stated John Ryals, Ph.D., CEO at Metabolon. “This collaboration between our two companies is an important step toward making Quantose IR and future precision medicine and diagnostics products widely available across the globe.”
Insulin resistance status can be a cornerstone of successful disease prevention and management. If caught early, physicians and patients can work together to prevent type 2 diabetes and other serious health conditions. Knowing the unique insulin resistance score for each patient enables physicians to identify and better manage individuals at the greatest risk for disease development or progression.
“Product innovation is key to SYNLAB’s objective of making medical innovation quickly available to medical experts and their patients. Working with Metabolon and licensing the Quantose IR technology adds another innovative offering to our laboratory services,” said Dr. Santiago Valor, Chief Medical Officer at SYNLAB Group. “The detection of insulin resistance will enable physicians to identify patients earlier for disease prevention and stratify patients by risk of disease progression.”